China Recombinant Protein Drug Industry Report, 2014-2017
  • Nov.2014
  • Hard Copy
  • USD $2,700
  • Pages:127
  • Single User License
    (PDF Unprintable)       
  • USD $2,500
  • Code: ZYM060
  • Enterprise-wide License
    (PDF Printable & Editable)       
  • USD $3,900
  • Hard Copy + Single User License
  • USD $2,900
      

The Chinese recombinant protein drug market has been expanding rapidly owing to the improvement of demand rigidity, consumption ability and the like. During 2005-2013, sales of recombinant protein drugs available in Chinese sample hospitals grew at a CAGR of 19.1%, and it is projected that China will see its actual demand for recombinant protein drugs exceed RMB40 billion in 2014.

The start of recombinant protein drugs in China is not late and common drugs are diversified in variety, for example, recombinant human erythropoietin (rhEPO), recombinant human granulocyte colony-stimulating factor (rhG-CSF) and recombinant human interferon (rhIFN) have gained market approval in the 1990s. Moreover, in 2013, domestic rhG-CSF, rhEPO and recombinant human growth hormone (rhGH) with price advantage took a respective share of 82.1%, 88.5% and 90.2% in Chinese sample hospitals, and recombinant human interleukin-2/11(rhIL-2/11) was fully localized.

However, as compared with products from leading bio-pharmaceutical enterprises in the United States and Europe, domestic recombinant protein drugs are still characterized by low-end technologies and largely remain in common short-acting areas. And foreign brands still prevail in the markets of recombinant insulin, rhIFN, recombinant coagulation factor and recombinant human follicle-stimulating hormone (rhFSH).

1. Recombinant Insulin Market. In 2013,foreign brands such asNovo Nordisk’s insulin aspart and insulin detemir, Sanofi’s insulin glargine, Eli Lilly’s insulin lispro accounted for 91.4% of recombinant insulin market of Chinese sample hospitals, while domestic insulin e.g. insulin glargine and insulin lispro of Gan & Lee Pharmaceuticals, recombinant insulin of Tonghua Dongbao Pharmaceuticaland animal insulin of Wanbang Biopharmaceuticalswas at a distinct disadvantage, whereas insulin analog products of Gan & Lee are still in the process of development, with huge potential for growth in the future.

2. rhIFN-αMarket.Roche's PEG-IFNα-2a, MSD’s PEG-IFNα-2a and IFN-α-2a, and other imported products still dominate Chinese interferon market, sweeping as much as 70.7% of recombinant interferon market of sample hospitals in 2013; whilemore than a dozen local companies like Shanghai Huaxin High Biotechnology Inc., Beijing Tri-Prime Genetic Engineering Co., Ltd. and Anhui Anke Biotechnology (Group) Co., Ltd.mainly produce ordinary short-acting products, which lack strong competitiveness compared with PEG-Intron products (long-acting interferon)with better anti-hepatitisvirus effect.

Moreover, there is no domestic recombinant protein drug in such markets as rhIFN-β, rhFSH, recombinant coagulation factor VIIa and factorVIIIyet.

Based on support from favorable policies, R&D ability enhancement as well as being optimistic about market prospects, a large number of biotech companies are vigorously developing long-acting, high-end protein drugs.?

In August 2014, PEG-rhGHof GeneScience Pharmaceuticals Co., Ltd. (GenSci, a subsidy of Changchun High & New Technology Industry (Group) Inc.) obtained the GMP certificate and could formally go on sale; however, as PEG-rhGHbelongs to national new First-in-Class drugs, a phase IV clinical trial is a must, and mass production is expected to begin in 2016. In June 2014, Anke Biotechnology’s PEG-rhIFNαand Dongbao Pharmaceutical’sultrolente insulin (insulin glargine)were both approved for clinical application. So far,PEG-GCSF of Jiangsu Hengrui Medicine Co., Ltd., PEG-rhIFNαof Xiamen Amoytop Biotech Co., Ltd. (a subsidiary of Dongbao Pharmaceutical) and rhFSH of GenSci have all declared for production and are expected to be approved and availableon the market in 2015.

蛋白重组药物 英文_副本.png


China Recombinant Protein Drug Industry Report, 2014-2017 highlights the followings:
20120114.gifMarket size, competition pattern, market segments, prospects, etc. of recombinant protein drugs worldwide;
20120114.gifMarket situation, competition pattern, R&D, forecasts for2014-2017, etc. of recombinant protein drugs in China;
20120114.gifDevelopment status, competition pattern, prospects, etc. of product segments e.g. recombinant insulin, rhG-CSF, rhEPO, rhGH, rhFSH in China;
20120114.gifOperation, recombinant protein drug business, forecast, etc. of 10 keyrecombinant protein drug enterprises in China (including Anhui Anke Biotechnology (Group) Co., Ltd., 3SBio Inc., Livzon Pharmaceutical Group Inc., Tonghua Dongbao Pharmaceutical Co., Ltd., etc.).

1. Overview of Recombinant Protein Drug Industry
1.1 Definition
1.2 Classification

2. Development of Recombinant Protein Drugs in China
2.1 Market Worldwide
2.2 Market Segments Worldwide
2.2.1 Insulin
2.2.2 Recombinant Human Interferon (rhIFN)
2.2.3 Recombinant Human Erythropoietin (rhEPO)
2.2.4 Recombinant Human Granulocyte Colony-stimulating Factor (rhG-CSF)
2.2.5 Recombinant Human Growth Hormone (rhGH)
2.2.6 Recombinant Human Follicle-stimulating Hormone (rhFSH)
2.3 Market in China
2.3.1 Market Size
2.3.2 Competition Pattern
2.4 Prospects
2.4.1 Market Worldwide
2.4.2 Market in China

3. Recombinant Protein Drug Market Segments in China
3.1 Recombinant Insulin
3.1.1 Development Status
3.1.2 Competition Pattern
3.1.3 Prospects
3.2 Recombinant Human Interferon (rhIFN)
3.2.1 Development Status
3.2.2 Competition Pattern
3.2.3 Prospects
3.3 Recombinant Human Granulocyte Colony-stimulating Factor (rhG-CSF)
3.3.1 Development Status
3.3.2 Competition Pattern
3.3.3 Prospects
3.4 Recombinant Human Follicle-stimulating Hormone (rhFSH)
3.4.1 Development Status
3.4.2 Competition Pattern
3.4.3 Prospects
3.5 Recombinant Human Erythropoietin (rhEPO)
3.5.1 Development Status
3.5.2 Competition Pattern
3.5.3 Prospects
3.6 Recombinant Human Growth Hormone (rhGH)
3.6.1 Development Status
3.6.2 Competition Pattern
3.6.3 Prospects
3.7 Others
3.7.1 Recombinant Coagulation Factor
3.7.2 Interleukin

4. Major Recombinant Protein Companies in China
4.1 3SBio Inc.
4.1.1 Profile
4.1.2 Operation
4.1.3 Revenue Structure
4.1.4 Gross Margin
4.1.5 R&D and Investment
4.1.6 Recombinant Protein Business
4.2 Uni-Bio Science Group Limited
4.2.1 Profile
4.2.2 Operation
4.2.3 Revenue Structure
4.2.4 Gross Margin
4.2.5 R&D and Investment
4.2.6 Recombinant Protein Business
4.2.7 Major Clients and Suppliers
4.3 Shenzhen Neptunus Interlong Bio-Technique Co., Ltd.
4.3.1 Profile
4.3.2 Operation
4.3.3 Revenue Structure
4.3.4 Gross Margin
4.3.5 R&D and Investment
4.3.6 Recombinant Protein Business
4.3.7 Major Clients and Suppliers
4.4 Essex Bio-Technology Limited
4.4.1 Profile
4.4.2 Operation
4.4.3 Gross Margin
4.4.4 Recombinant Protein Business
4.4.5 Major Clients and Suppliers
4.5 Livzon Pharmaceutical Group Inc.
4.5.1 Profile
4.5.2 Operation
4.5.3 Revenue Structure
4.5.4 Gross Margin
4.5.5 Clients
4.5.6 R&D and Investment
4.5.7 Recombinant Protein Business
4.5.8 Outlook and Forecast
4.6 Changchun High & New Technology Industry (Group) Inc.
4.6.1 Profile
4.6.2 Operation
4.6.3 Revenue Structure
4.6.4 Gross Margin
4.6.5 Clients
4.6.6 R&D and Investment
4.6.7 Recombinant Protein Business
4.6.8 Outlook and Forecast
4.7 Anhui Anke Biotechnology (Group) Co., Ltd.,  
4.7.1 Profile
4.7.2 Operation
4.7.3 Revenue Structure
4.7.4 Gross Margin
4.7.5 Clients
4.7.6 R&D and Investment
4.7.7 Recombinant Protein Business
4.7.8 Outlook and Forecast
4.8 Tonghua Dongbao Pharmaceutical Co., Ltd. 
4.8.1 Profile
4.8.2 Operation
4.8.3 Revenue Structure
4.8.4 Gross Margin
4.8.5 Clients
4.8.6 R&D and Investment
4.8.7 Recombinant Protein Business
4.8.8 Outlook and Forecast
4.9 Beijing SL PHarmaceutical Co., Ltd.
4.9.1 Profile
4.9.2 Operation
4.9.3 Revenue Structure
4.9.4 Gross Margin
4.9.5 Clients
4.9.6 R&D and Investment
4.9.7 Recombinant Protein Business
4.9.8 Outlook and Forecast
4.10 Jiangsu Shihuan Bioengineering Co., Ltd.
4.10.1 Profile
4.10.2 Operation
4.10.3 Revenue Structure
4.10.4 Gross Margin
4.10.5 Clients
5.10.6 R&D and Investment
4.10.7 Recombinant Protein Business
4.10.8 Outlook and Forecast

5. Summary and Forecast
5.1 Summary
5.2 Forecast
Production Process of Recombinant Protein Drugs
Classification and Indications of Recombinant Protein Drugs
Market Size and YoY Growth of Recombinant Protein Drugs Worldwide, 2007-2014
Competition Pattern of Recombinant Protein Drugs Worldwide (by Product), 2013
Competition Patternof Recombinant Protein Drugs Worldwide (by Enterprise), 2013
Classification of Insulin (by Technological Levelor Time)
Market Size and YoY Growth of Insulin Worldwide, 2007-2014
Competition Pattern of Insulin Worldwide (by Enterprise), 2013
Market Size of Interferon Worldwide, 2007-2014
Competition Pattern of Interferon Worldwide (by Product or Enterprise), 2013
Market Size of rhEPO Worldwide, 2007-2014
Competition Pattern of rhEPO Worldwide (by Product or Enterprise), 2013
Market Size of rhG-CSF Worldwide, 2007-2014
Competition Patternof rhG-CSF Worldwide (by Product or Enterprise), 2007-2014
rhGH Indications Approved in the U.S. and China up to Now
Market Size of rhGH Worldwide, 2007-2014
Competition Pattern of rhGH Worldwide (by Product or Enterprise), 2007-2014
Sales of Recombinant Protein Drugs of Sample Hospitals in China, 2007-2014
Competition Pattern of Recombinant Protein Drugs of Sample Hospitals in China (by Product), 2013
Percentage of Domestic and Imported Recombinant Protein Drugs of Sample Hospitals in China (by Amount), 2007-2014
Competition Patternof Recombinant Protein Drugs of Sample Hospitals in China (by Enterprise), 2013
Number of Diabetics in China, 2011-2013
Market Size of Insulin Drugs in China, 2007-2014
Competition Pattern of Insulin Market in China (by Enterprise), 2013
Market Size of Insulin Drugs in China, 2013-2017E
Competition Patternof rhIFN of Sample Hospitals in China (by Product), 2013
Market Size of rhIFN in China, 2007-2014
Competition Pattern of rhIFN of Sample Hospitals in China (by Enterprise), 2013
Prices of Major Interferon Products in China, 2013-2014
Forecast for Market Capacity of rhIFN for Hepatitis Treatment in China
R&D of Major Interferon Products in China as of end-Sept. 2014
Competition Patternof rhG-CSF of Sample Hospitals in China (by Enterprise), 2013
Diseases Lethal to Rural Residents in China, 2012
R&D of Major PEG-rhG-CSF in China as of end-Sept. 2014
Costs of Treatment with Major FSH Products in China, 2012-2014
Competition Patternof FSH of Sample Hospitals in China (by Enterprise), 2013
Costs of Treatmentwith Major EPO Products in China
Market Competition Pattern of rhGH of Sample Hospitals in China (by Enterprise), 2013 
Costs of Treatment with Major rhGH Products in China, 2012-2014
Lot Release Quantity and Growth Rate of Coagulation Factor VIII in China, 2008-2013
Revenue and Profit of 3SBio, 2007-2012
Revenue Structure of 3SBio, 2007-2012
Revenue Breakdown of 3SBio(by Product), 2007-2012
Gross Profit and Consolidated Gross Margin of 3SBio, 2007-2012
R&D Costs and % of Total Revenue of 3SBio, 2008-2012
R&D Cost Structure of 3SBio, 2008-2012
R&D Costs of 3SBio (by Product), 2008-2012
Key R&D Business of 3SBio, 2013
Major Recombinant Protein Products of 3SBio
Revenue and Profit of Uni-Bio Science, FY2008-FY2014
Revenue Structure of Uni-Bio Science (by Industry), FY2008-FY2014
Revenue Breakdown of Uni-Bio Science (by Industry), FY2008-FY2014
Gross Profit and Gross Margin of Uni-Bio Science, FY2008-FY2014
Products under R&D and Progress of Uni-Bio Science, FY2014
Uni-Bio Science’s Revenue and Pretax Profit from Biological Drugs, FY2008-FY2014
Uni-Bio Science’s Revenue Percentage from Top 5 Clients, FY2008-FY2014
Uni-Bio Science’s Procurement Percentage from Top 5 Suppliers, FY2008-FY2014
Revenue and Net Income of Neptunus Interlong Bio-Technique, 2008-2014
Revenue Structure of Neptunus Interlong Bio-Technique (by Product), 2009-2014
Revenue Breakdown of Neptunus Interlong Bio-Technique (by Product), 2009-2014
Gross Profit and Gross Margin of Neptunus Interlong Bio-Technique, 2008-2014
Neptunus Interlong Bio-Technique’s Revenue Percentage from Top 5 Clients, 2011-2013
Neptunus Interlong Bio-Technique’s Procurement Percentage from Top 5 Suppliers, 2011-2013
Revenue and Net Income of Essex Bio-Technology, 2009-2014
Gross Profit and Gross Margin of Essex Bio-Technology, 2009-2014
Recombinant Protein Products of Essex Bio-Technology
Essex Bio-Technology’s Revenue Percentage from Top 5 Clients, 2009-2014
Essex Bio-Technology’s Procurement Percentage from Top 5 Suppliers, 2009-2014
Revenue and Net Income of Livzon Pharmaceutical Group, 2008-2014
Operating Revenue Structure of Livzon Pharmaceutical Group (by Region), 2008-2014
Revenue Breakdown of Livzon Pharmaceutical Group (by Region), 2008-2014
Operating Revenue Structure of Livzon Pharmaceutical Group (by Product), 2008-2013
Revenue Breakdown of Livzon Pharmaceutical Group (by Product), 2008-2013
Livzon Pharmaceutical Group’s Revenue Breakdown and Percentage by Products, 2014H1
Consolidated Gross Margin of Livzon Pharmaceutical Group, 2008-2014
Gross Margin of Livzon Pharmaceutical Group (by Product), 2008-2013
Gross Margin of Livzon Pharmaceutical Group (by Product), 2014H1
Livzon Pharmaceutical Group’s Revenue from Top 5 Clients and % of Total Revenue, 2008-2014
Revenue and Gross Margin of Gonadotropin Products of Livzon Pharmaceutical Group, 2008-2014
Revenue and Net Income of Livzon Pharmaceutical Group, 2014-2017E
Revenue and Net Income of Changchun High & New Technology, 2008-2014
Operating Revenue Structure of Changchun High & New Technology (by Region), 2008-2014
Revenue Breakdown of Changchun High & New Technology (by Region), 2008-2014
Operating Revenue Structure of Changchun High & New Technology (by Industry), 2008-2014
Revenue Breakdown of Changchun High & New Technology (by Industry), 2008-2014
Consolidated Gross Margin of Changchun High & New Technology, 2008-2014
Gross Margin of Changchun High & New Technology (by Region), 2008-2014
Gross Margin of Changchun High & New Technology (by Industry), 2008-2014
Changchun High & New Technology’s Revenue from Top 5 Clients and % of Total Revenue, 2008-2014
Progress of R&D Projects of Changchun High & New Technology, as of June 2014
Changchun High & New Technology’s Revenue from Biological Drugs and % of Total Revenue, 2008-2014
Gross Margin of Biological Drugs of Changchun High & New Technology, 2008-2014
Revenue and Net Income of GenSci, 2009-2014
Consolidated Gross Margin of GenSci, 2009-2014
Revenue and Net Income of Changchun High&New Technology, 2014-2017E
Revenue and Net Income of Anhui Anke Biotechnology, 2008-2014
Operating Revenue Structure of Anhui Anke Biotechnology (by Region), 2008-2014
Revenue Breakdown of Anhui Anke Biotechnology (by Region), 2008-2014
Operating Revenue Structure of Anhui Anke Biotechnology in China (by Region), 2009-2014
Revenue Breakdown of Anhui Anke Biotechnology in China (by Region), 2009-2014
Operating Revenue Structure of Anhui Anke Biotechnology (by Industry), 2008-2014
Revenue Breakdown of Anhui Anke Biotechnology (by Industry), 2008-2014
Consolidated Gross Margin of Anhui Anke Biotechnology, 2008-2014
Gross Margin of Anhui Anke Biotechnology (by Region), 2008-2014
Gross Margin of Anhui Anke Biotechnology (by Industry), 2008-2014
Anhui Anke Biotechnology’s Revenue from Top 5 clients and % of Total Revenue, 2009-2014
R&D Costs and % of Total Revenue of Anhui Anke Biotechnology, 2008-2013
Anhui Anke Biotechnology’s Revenue from Interferon and % of Total Revenue, 2009-2014
Gross Margin of Interferon of Anhui Anke Biotechnology, 2009-2014
Anhui Anke Biotechnology’s Revenue from GH and % of Total Revenue, 2009-2014
Gross Margin of GH of Anhui Anke Biotechnology, 2009-2014
Revenue and Net Income of Anhui Anke Biotechnology, 2014-2017E
Revenue and Net Income of Dongbao Pharmaceutical, 2008-2014
Operating Revenue Structure of Dongbao Pharmaceutical (by Region), 2008-2014
Revenue Breakdown of Dongbao Pharmaceutical (by Region), 2008-2014
Operating Revenue Structure of Dongbao Pharmaceutical (by Industry), 2008-2014
Revenue Breakdown of Dongbao Pharmaceutical (by Industry), 2008-2014
Consolidated Gross Margin of Dongbao Pharmaceutical, 2008-2014
Gross Margin of Dongbao Pharmaceutical (by Industry), 2008-2014
Dongbao Pharmaceutical’s Revenue from Top 5 clients and % of Total Revenue, 2009-2014
Dongbao Pharmaceutical’s revenue from Recombinant Human Insulin and % of Total Revenue, 2009-2014
Gross Margin of Recombinant Human Insulin of Dongbao Pharmaceutical, 2009-2014
Revenue and Net Income of Dongbao Pharmaceutical, 2014-2017E
Revenue and Net Income of SL Pharm, 2008-2014
Operating Revenue Structure of SL Pharm (by Region), 2010-2014
Revenue Breakdown of SL Pharm (by Region), 2010-2014
Operating Revenue Structure of SL Pharm (by Industry), 2010-2014
Revenue Breakdown of SL Pharm (by Industry), 2010-2014
Consolidated Gross Margin of SL Pharm, 2008-2014
Gross Margin of SL Pharm (by Industry), 2010-2014
SL Pharm’s Revenue from Top 5 Clients and % of Total Revenue, 2008-2014
R&D Costs and % of Total Revenue of SL Pharm, 2008-2013
Output and Sales Volume of Biological and Biochemical Drugs of SL Pharm, 2011-2013
Revenue and Net Income of SL Pharm, 2014-2017E
Revenue and Net Income of Shihuan Bioengineering, 2008-2014
Operating Revenue Structure of Shihuan Bioengineering (by Region), 2009-2014
Revenue Breakdown of Shihuan Bioengineering (by Region), 2009-2014
Operating Revenue Structure of Shihuan Bioengineering (by Product), 2011-2014
Revenue Breakdown of Shihuan Bioengineering (by Product), 2011-2014
Consolidated Gross Margin of Shihuan Bioengineering, 2008-2014
Gross Margin of Shihuan Bioengineering (by Product), 2011-2014
Shihuan Bioengineering’s Revenue from Top 5 Clients and % of Total Revenue, 2008-2014
Revenue and Gross Margin of Interleukin of Shihuan Bioengineering, 2008-2014
Revenue and Gross Margin of EPO of Shihuan Bioengineering, 2008-2014
Revenue and Gross Margin of G-CSF of Shihuan Bioengineering, 2011-2014
Revenue and Net Income of Shihuan Bioengineering, 2014-2017E
Comparison among Sales Growth Rates of Major Recombinant Protein Drugs of Sample Hospitals in China, 2005-2013
Market Competition of Various Genetically Engineered Drugs in China, as of end-Sep.2014
R&D of High-end Recombinant Protein Drugs in China (Partial), as of Sep.2014

China Independent Clinical Laboratory Industry Report, 2019-2025

China's independent clinical laboratory industry is still in its infancy. In 2018, it only saw the penetration rate of about 5%, far below 40% or more in Europe, the United States and Japan. The main ...

Global and China Monoclonal Antibody Industry Report, 2019-2025

Global monoclonal antibody market can be presented as follows: 1. Monoclonal antibody drug market booms and is highly concentrated with the approvals for such drugs.Monoclonal antibody drugs have bee...

China Contract Research Organization (CRO) Industry Report, 2019-2025

The steadily growing global pharmaceutical industry where more and more new drugs have been approved, and the soaring spending on drug research and development in recent years, are a boon for global c...

China Blood Product Industry Report, 2019-2025

With the adjustment of the national medical insurance catalogue, the clinical application and reimbursement rate of almost all blood products have been greatly improved, and the market for blood produ...

China Human Vaccine Industry Report, 2018-2022

As the world’s largest producer of human vaccines, China has established a full-life-cycleregulatory system covering vaccine R&D, production, distribution, and vaccination. The lot release volum...

China Contract Research Organization(CRO) Industry Report, 2017-2021

Under the pressure from higher R&D costs, longer R&D cycle and lower R&D success rate in pharmaceutical industry worldwide, over 50 percent of pharmaceutical enterprises have had the devel...

China Vacuum Blood Collection Device Industry Report, 2017-2021

China’s vacuum blood collection device industry now flourishes after start-up and growth stages. Along with steady improvement in economic environment, rising per-capita disposable income, greater awa...

China Independent Clinical Laboratory Industry Report, 2017-2021

China's independent clinical laboratory industry started late, and is still in its infancy. In 2016, it only saw the penetration rate of about 4%, far below 40% or more in Europe, the United States an...

China Human Vaccine Industry Report, 2017-2021

The human vaccine industry presented the following main characteristics in 2016 in China: 1. Lot release volume of human vaccines declined.Affected by the illegal vaccine case in Mar 2016 in Shandong...

China Independent Clinical Laboratory Industry Report, 2016-2020

Owing to a large population base, uneven distribution of medical resources among regions, aging population, and continuous advance of health care reform, the Chinese independent clinical laboratory ma...

China Human Vaccine Industry Report, 2016-2020

Amid the unsafe domestic vaccine events, China’s human vaccine lot release volume in 2015 fell by 17.9% year on year to only 650 million doses,touching a 5-year low. Moreover, with the improvements in...

China Animal Vaccine Industry Report, 2016-2020

Animal vaccine is a kind of biological agent that enables inoculated animals to produce active immunity for disease prevention. In recent years, European and American animal vaccine markets have seen ...

China Blood Product Industry Report, 2016-2019

Recombinant blood products have developed for many years in foreign countries, but China’s blood products are still proteins extracted from human blood. Thus, reserves and control of plasma resources ...

China Contract Research Organization (CRO) Industry Report, 2015-2018

In recent years, China's contract research organization (CRO) industry has developed rapidly, with the market size rising from RMB8.5 billion in 2007 to RMB42.6 billion in 2014, registering a CAGR of ...

Global and China Industrial Enzyme Industry Report, 2014-2017

In recent years, the global industrial enzyme preparation market size increased year by year, registering a CAGR of 5%, approximating USD4.2178 billion in 2014. At present, the global industrial enzym...

China Blood Product Industry Report, 2015-2018

Recombinant blood products have developed for many years in foreign countries, but China’s blood products are still proteins extracted from human blood. Thus, reserves and control of plasma resources ...

China Human Vaccine Industry Report, 2015-2018

A vaccine is a preventive biological product for human use that prevents and controls the occurrence and prevalence of infectious diseases, so the demand for such products is relatively rigid. Due to ...

China Vacuum Blood Collection Industry Report, 2014-2017

The vacuum blood collection system consisting of vacuum blood collection tubes, disposable blood collection needles, tourniquets, etc transfers human venous blood to closed containers and makes it int...

2005-2014 www.researchinchina.com All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号
在线客服系统